Precision Therapeutic Platforms

Platforms engineered
for biological change

SholoCARE is building precision therapeutic platforms that operate beyond the limits of conventional drugs, integrating small-molecule discovery, intracellular biologics, and adaptive antiviral systems.

0 Therapeutic Platforms
0 Disease Areas
∞ Scalable Design
SholoCARE: Discover to Recover
Our Discovery Engine

Cancer and viral pathogens evolve under pressure.
Most discovery platforms do not.

SholoCARE's Discovery Engine is built to identify biologics that remain functional in living systems, not just molecules that look promising in vitro. Rather than optimizing for isolated binding events, our approach prioritizes behavior under biological constraint.

At every stage, candidates are evaluated for their ability to:

  • Operate inside cells, not just on their surface
  • Remain active in dynamic, stress-driven environments
  • Sustain function as biological conditions change

This means our discovery process is intentionally selective. Many molecules that meet traditional benchmarks never advance. Only candidates that demonstrate intrinsic delivery, intracellular activity, and functional persistence move forward.

By embedding real biological pressure into discovery early and repeatedly, we enrich for therapeutics capable of performing where disease actually lives. The result is a pipeline designed not for static targets, but for adaptive pathology.

scFv, VHH, Small Molecules Peptides to Small Molecules
Problem & Mission

Most therapies fail not because disease drivers are unknown, but because they are unreachable.

SholoCARE was founded to overcome this barrier by developing therapeutic platforms capable of acting inside cells, adapting to biological complexity, and addressing diseases that evade today's static treatments.

We build platforms first and programs second, ensuring scalability across oncology, infectious disease, and emerging biological threats.

01

Act Inside Cells

Targeting disease biology where it actually lives, beyond the membrane barrier that conventional drugs cannot cross.

02

Adapt to Complexity

Systems designed not to fail when biology mutates or resistance develops, built with change in mind.

03

Scale Across Disease

Platforms that serve oncology, infectious disease, and emerging threats without being rebuilt from scratch.

Platform Vision

SholoCARE is advancing a new generation of
therapeutic platforms

We don't chase targets. We build systems that keep working when biology changes.

Let's build the future of medicine.

For more information about SholoCARE's programs please contact us.

contact@sholocare.com
📍  Maryland, USA
Technology

Three complementary,
independently defensible platforms

SholoCARE's discovery engine powers three distinct platforms, each capable of standing alone, yet designed to reinforce one another across oncology, infectious disease, and emerging biological threats.

  • Platform I: Small-molecule translation from peptide & protein binders
  • Platform II: CYTOPRISM™ Intracellular functional biologics
  • Platform III: VIRTOPRISM™ Adaptive intracellular antiviral defense
Phage Display Technology
Platform I
Small-Molecule
Translation Engine
Discovery

Engineered to translate complex biological interactions into scalable, drug-like small molecules. Our engine bridges intractable biology and clinically viable therapeutics.

  • Non-canonical regulatory binding site discovery
  • Peptide-to-small-molecule translation pipeline
  • Resistance-aware molecular design framework
  • Oral bioavailability optimization at every stage
Peptide, Small Molecules, Antibodies, Protein
Platform II
CYTOPRISM™
Biologics

Intracellular Functional Biologics. CYTOPRISM™ enables direct modulation of intracellular targets using non-viral, non-integrating delivery, with modular architecture built for function, not just binding.

  • Direct intracellular modulation of disease targets
  • Non-viral, non-integrating delivery mechanism
  • Function-first design philosophy
  • Modular architecture adaptable across target classes
scFv, VHH, Small Molecules
Platform III
VIRTOPRISM™
Antiviral

Intracellular antiviral defense systems. VIRTOPRISM™ targets conserved viral components inside infected cells, with broad applicability and built-in mutation resilience, reconfigurable as threats evolve.

  • Targets conserved viral components inside cells
  • Broad applicability across enveloped virus families
  • Designed for mutation resilience
  • Rapid reconfiguration against emerging variants
Antibodies, Peptides, Proteins, Small Molecules
The SholoCARE Difference

A new model for therapeutic development

Conventional Model

  • Single-asset focus
  • Static mechanisms
  • Delivery-limited
  • Narrow scope

SholoCARE Model

  • Multi-platform architecture
  • Intracellular functional strategies
  • Function-driven design
  • Cross-disease scalability
Cross-Platform Principles

Principles that unify our work

Intracellular SpecificityPrecision where biology operates, inside the cell, not around it.
Modularity & ReusePlatforms built to be repurposed across targets without being rebuilt.
Biological AdaptationSystems that remain effective as biology evolves and resists.
Scalable TranslationCross-disease applicability baked in from the discovery stage forward.

Ready to learn more?

For more information about SholoCARE's programs please contact us.

contact@sholocare.com
📍  Maryland, USA
About SholoCARE

Built on science.
Driven by purpose.

SholoCARE is a platform-driven biotechnology company focused on developing precision medicine systems capable of reaching disease biology beyond the limits of conventional medicines.

SholoCARE Logo Mark

Who We Are

SholoCARE is a platform-driven biotechnology company focused on developing precision medicine systems capable of reaching disease biology beyond the limits of conventional medicines.

Our work spans oncology, infectious disease, and emerging biological threats, three areas united by a single challenge: reaching the biology that matters, reliably and at scale.

Scientific Leadership

SholoCARE is led by scientists with experience spanning molecular biology, therapeutic design, and translational execution.

Our team combines depth of expertise with a shared conviction: that the biggest barriers in medicine are not scientific unknowns, but engineering challenges waiting for the right platform.

Disease Focus

Two categories of unreachable biology

Cancer Targets and Infectious Disease Targets
Our Philosophy
"Discover to Recover"

Discover to Recover reflects our belief that discovery must be deliberate, recovery requires precision, and meaningful medicine begins with reaching the right biology.

Evidence-BasedEvery decision anchored in data, not dogma.
Platform LeveragePrograms emerge from platforms, never the reverse.
Clear GatesDevelopment milestones that are honest, measurable, and respected.
Responsible RiskWe take the right risks, the ones science justifies.

Work with us.

For more information about SholoCARE's programs please contact us.

contact@sholocare.com
📍  Maryland, USA